返回 Agenda
Session 12: The Lifecycle of a REMS
Session Chair(s)
Jill K. Logan, PharmD
Safety Evaluator, DPV I, OSE, CDER
FDA, United States
Ingrid N. Chapman, PharmD
Senior Risk Management Analyst, DRM, OMEPRM, OSE, CDER
FDA, United States
Risk evaluation and mitigation strategies (REMS) are drug safety programs required by FDA and developed by manufacturers to ensure the benefit of a drug or biologic product outweighs its risk. Risk management is an iterative process that includes assessing the drug’s benefit-risk balance, developing and implementing tools to minimize risks while preserving benefits, evaluating the effectiveness of the intervention(s) and adjusting, as appropriate. REMS are designed to mitigate a specific risk by reinforcing medication use behaviors and actions that support the safe use of the drug product. Following approval of a REMS, it is important to assess the effectiveness of the REMS and to consider if there are opportunities to improve the implementation of the REMS to reduce the burden to stakeholders. This session examines REMS development, implementation, assessments, and modifications which will be discussed and illustrated with examples.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Link interventions to measurable outcomes
- Identify pathways to REMS modifications
- Discuss how post-marketing data or assessments may impact the REMS and lead to modification
Speaker(s)
Speaker
Shelly Harris, DrSc, MPH
FDA, United States
REMS Assessment Team Leader, OSE, CDER
Speaker
Catherine Baldridge, MSc
Fusion Pharmaceuticals, United States
Head of Safety
REMS Changes Over Time
Elisa Gomez-Reino, MPH
Alexion Pharmaceuticals, Inc., United States
Senior Director, Regional Safety Excellence US and Canada